Clearmind aims to initiate clinical trials with CMND-100 by year’s end
Vancouver, May 13, 2022 — Clearmind Medicine Inc. (CSE: CMND, OTC Pink:CMNDF, FSE: CWY0) (“Clearmind” or the „Company„), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under treated health problems, today announced that it will meet with the Centre for Drug Evaluation and Research (“CDER”) of the U.S. Food and Drug Administration (“FDA”) on Wednesday, May 18, 2022. The meeting is to discuss numerous aspects of Clearmind’s planned First in Human (“FIH”) study evaluating its proprietary drug candidate CMND-100 for the treatment of Alcohol Use Disorder (“AUD”)…